Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.45. Which is the better fit depends on your goals.
| RXRX | TLT | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | — |
52-Week High | $6.79 | $92.06 |
52-Week Low | $2.84 | $82.05 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
TLT trades at $82.76, up 0.29% on the day, while technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and concerns about U.S. debt levels nearing $40 trillion. Recent institutional activity includes Ferguson Shapiro LLC purchasing 37,900 shares, indicating some professional interest despite the challenging environment.
The outlook remains cautious as rising oil prices and inflation concerns continue to pressure long-term bond yields higher. Investment opportunities exist for income-focused investors through TLT's dividend payments, but risks include Federal Reserve policy uncertainty and geopolitical tensions affecting Treasury markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
